Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04513912
Registration number
NCT04513912
Ethics application status
Date submitted
13/08/2020
Date registered
14/08/2020
Date last updated
13/09/2023
Titles & IDs
Public title
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Query!
Scientific title
Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Query!
Secondary ID [1]
0
0
42847922MDD3005
Query!
Secondary ID [2]
0
0
CR108810
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depressive Disorder, Major
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Seltorexant
Treatment: Drugs - Matching placebo to Seltorexant
Treatment: Drugs - Quetiapine XR
Treatment: Drugs - Matching placebo to Quetiapine XR
Experimental: Seltorexant - Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
Active Comparator: Quetiapine Extended-Release (XR) - Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
Treatment: Drugs: Seltorexant
Participants will receive seltorexant over-encapsulated tablet orally.
Treatment: Drugs: Matching placebo to Seltorexant
Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
Treatment: Drugs: Quetiapine XR
Participants will receive quetiapine XR capsule orally.
Treatment: Drugs: Matching placebo to Quetiapine XR
Participants will receive placebo capsule matching to quetiapine XR orally.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants with Response (>=50 Percent improvement in MADRS total score from baseline) at Week 26
Query!
Assessment method [1]
0
0
Responders are defined as percentage of participants with greater than or equal to (>=) 50 percent (%) improvement in the montgomery-asberg depression rating scale (MADRS) total score from baseline. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Query!
Timepoint [1]
0
0
Week 26
Query!
Secondary outcome [1]
0
0
Change from baseline in Weight up to Week 26
Query!
Assessment method [1]
0
0
Change from baseline in weight will be reported.
Query!
Timepoint [1]
0
0
Baseline to Week 26
Query!
Secondary outcome [2]
0
0
Time to Study Drug Discontinuation for Potentially Treatment Related Reasons
Query!
Assessment method [2]
0
0
Time to discontinuation of study drug for potentially treatment related reasons will be reported. Potentially treatment related reasons are defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (eg, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances).
Query!
Timepoint [2]
0
0
Up to Week 26
Query!
Secondary outcome [3]
0
0
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Query!
Assessment method [3]
0
0
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Query!
Timepoint [3]
0
0
Baseline to Week 26
Query!
Secondary outcome [4]
0
0
Change from Baseline in MADRS-6 Total Score
Query!
Assessment method [4]
0
0
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: Apparent Sadness, Reported Sadness, Inner Tension, Lassitude, Inability to Feel, and Pessimistic Thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms).
Query!
Timepoint [4]
0
0
Baseline to Week 26
Query!
Secondary outcome [5]
0
0
Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Query!
Assessment method [5]
0
0
The MADRS is a 10-item clinician-rated instrument for evaluating severity of symptoms of depression. Each item is rated on a scale from 0 to 6, with higher scores indicating greater symptom severity. MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity.
Query!
Timepoint [5]
0
0
Baseline to Week 26
Query!
Secondary outcome [6]
0
0
Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Query!
Assessment method [6]
0
0
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.
Query!
Timepoint [6]
0
0
Baseline to Week 26
Query!
Secondary outcome [7]
0
0
Percentage of Participants with Remission (MADRS Total Score less than or equal to (<=) 12) at Week 26
Query!
Assessment method [7]
0
0
Percentage of participants with remission (MADRS total Score <=12) will be reported.
Query!
Timepoint [7]
0
0
Week 26
Query!
Secondary outcome [8]
0
0
Percentage of Participants with a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Query!
Assessment method [8]
0
0
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26.
Query!
Timepoint [8]
0
0
Week 26
Query!
Secondary outcome [9]
0
0
Percentage of Participants with Weight Increase >=7 Percent from Baseline at Week 26
Query!
Assessment method [9]
0
0
Percentage of participants with weight increase >=7 percent from baseline will be reported.
Query!
Timepoint [9]
0
0
Week 26
Query!
Eligibility
Key inclusion criteria
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5)
diagnostic criteria for major depressive disorder (MDD), without psychotic features,
based upon clinical assessment and confirmed by the structured clinical interview for
DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first
depressive episode prior to age 60. The length of the current depressive episode must
be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants,
administered at an adequate dose and duration in the current episode of depression.
The current antidepressant cannot be the first antidepressant treatment for the first
lifetime episode of depression. An inadequate response is defined as less than (<) 50
percent (%) reduction but with some improvement (that is, improvement greater than [>]
0%) in depressive symptom severity with residual symptoms present other than insomnia,
and overall good tolerability, as assessed by the Massachusetts General
Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake
inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive
symptoms at screening, in any formulation and available in the participating country:
citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran,
levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or
vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6
weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to
(>=) 20 at the first screening interview, must not demonstrate a clinically
significant improvement (that is, an improvement of > 20% on their HDRS-17 total
score) from the first to the second independent HDRS-17 rating, and must have a
HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a
clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive
(BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical
examination, vital signs (including blood pressure), and 12-lead electrocardiogram
(ECG) performed at screening and baseline
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
74
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe
renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per
minute [mL/min]); clinically significant or unstable cardiovascular, respiratory,
gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine
disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more
adequate antidepressant treatments in the current episode, as indicated by no or
minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate
dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder,
intellectual disability, autism spectrum disorder, borderline personality disorder,
somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use
disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive
sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia
disorder are allowed
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/09/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
4/10/2023
Query!
Actual
Query!
Sample size
Target
720
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oklahoma
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Utah
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Wisconsin
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Buenos Aires
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Cordoba
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
La Plata
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Mendoza
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
San Miguel de Tucuman
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Brugge
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Sint-Niklaas
Query!
Country [34]
0
0
Bulgaria
Query!
State/province [34]
0
0
Pleven
Query!
Country [35]
0
0
Bulgaria
Query!
State/province [35]
0
0
Plovdiv
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Ruse
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Sofia
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Stara Zagora
Query!
Country [39]
0
0
Bulgaria
Query!
State/province [39]
0
0
Tzarev Brod
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Varna
Query!
Country [41]
0
0
Bulgaria
Query!
State/province [41]
0
0
Veliko Tarnovo
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Nova Scotia
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Ontario
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Quebec
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Brno
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Hradec Kralove
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Plzen
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Praha 10
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Praha 6
Query!
Country [50]
0
0
Czechia
Query!
State/province [50]
0
0
Praha 8
Query!
Country [51]
0
0
Latvia
Query!
State/province [51]
0
0
Jelgava
Query!
Country [52]
0
0
Latvia
Query!
State/province [52]
0
0
Liepaja
Query!
Country [53]
0
0
Latvia
Query!
State/province [53]
0
0
Outpatient Centre Of Psychiatry
Query!
Country [54]
0
0
Latvia
Query!
State/province [54]
0
0
Riga
Query!
Country [55]
0
0
Lithuania
Query!
State/province [55]
0
0
Kaunas
Query!
Country [56]
0
0
Lithuania
Query!
State/province [56]
0
0
Silute
Query!
Country [57]
0
0
Lithuania
Query!
State/province [57]
0
0
Vilnius
Query!
Country [58]
0
0
Malaysia
Query!
State/province [58]
0
0
Ipoh
Query!
Country [59]
0
0
Malaysia
Query!
State/province [59]
0
0
Johor Bahru
Query!
Country [60]
0
0
Malaysia
Query!
State/province [60]
0
0
Pulau Pinang
Query!
Country [61]
0
0
Malaysia
Query!
State/province [61]
0
0
Seremban
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Belchatow
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Bialystok
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Bydgoszcz
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Gdansk
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Lodz
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Lublin
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Poznan
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Warsaw
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Warszawa
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Ekaterinburg
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Engels, Saratov Region
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Kemerovo
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Lipetsk Region
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Moscow
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Omsk
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
St. Petersburg
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Tomsk
Query!
Country [79]
0
0
Serbia
Query!
State/province [79]
0
0
Belgrade
Query!
Country [80]
0
0
Serbia
Query!
State/province [80]
0
0
Kovin
Query!
Country [81]
0
0
Serbia
Query!
State/province [81]
0
0
Kragujevac
Query!
Country [82]
0
0
Serbia
Query!
State/province [82]
0
0
Nis
Query!
Country [83]
0
0
Serbia
Query!
State/province [83]
0
0
Novi Knezevac
Query!
Country [84]
0
0
Slovakia
Query!
State/province [84]
0
0
Banska Bystrica
Query!
Country [85]
0
0
Slovakia
Query!
State/province [85]
0
0
Bojnice
Query!
Country [86]
0
0
Slovakia
Query!
State/province [86]
0
0
Koshice
Query!
Country [87]
0
0
Slovakia
Query!
State/province [87]
0
0
Liptovsky Mikulas
Query!
Country [88]
0
0
Slovakia
Query!
State/province [88]
0
0
Rimavska Sobota
Query!
Country [89]
0
0
Slovakia
Query!
State/province [89]
0
0
Trencin
Query!
Country [90]
0
0
Slovakia
Query!
State/province [90]
0
0
Zilina
Query!
Country [91]
0
0
Ukraine
Query!
State/province [91]
0
0
Glevakha
Query!
Country [92]
0
0
Ukraine
Query!
State/province [92]
0
0
Kharkiv
Query!
Country [93]
0
0
Ukraine
Query!
State/province [93]
0
0
Kyiv
Query!
Country [94]
0
0
Ukraine
Query!
State/province [94]
0
0
Nove, Kropyvnytskiy
Query!
Country [95]
0
0
Ukraine
Query!
State/province [95]
0
0
Ternopil
Query!
Country [96]
0
0
Ukraine
Query!
State/province [96]
0
0
Zaporizhzhia
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Derby
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Greater Manchester
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Harrogate
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
London
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Redruth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine
extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response
in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an
inadequate response to current antidepressant therapy with a selective serotonin reuptake
inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04513912
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-434-4210
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04513912
Download to PDF